<DOC>
	<DOCNO>NCT01689246</DOCNO>
	<brief_summary>The purpose study determine safety efficacy TRx0237 treatment subject mild moderate Alzheimer 's Disease .</brief_summary>
	<brief_title>Safety Efficacy Study Evaluating TRx0237 Subjects With Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Diagnosis cause dementia probable Alzheimer 's disease Clinical Dementia Rating ( CDR ) total score 1 ( mild ) 2 ( moderate ) MMSE score 1426 ( inclusive ) Age &lt; 90 year Modified Hachinski ischemic score ≤ 4 Females , childbearing potential , must practice true abstinence competent use adequate contraception agree maintain throughout study Subject , and/or , case reduce decisionmaking capacity , legally acceptable representative ( ) consistent national law is/are able read , understand , provide write informed consent Has one ( ) identify adult caregiver willing provide write informed consent his/her participation ; able read , understand , speak designate language study site ; either live subject see subject ≥2 hours/day ≥3 days/week ; agree accompany subject study visit ; able verify daily compliance study drug If currently take acetylcholinesterase inhibitor and/or memantine time Screening , subject must take medication ( ) ≥3 month . The dosage regimen must remain stable ≥6 week must plan remain stable throughout participation study . Able comply study procedure Significant central nervous system ( CNS ) disorder Alzheimer 's disease Significant focal vascular intracranial pathology see brain MRI scan Clinical evidence history stroke , transient ischemic attack , significant head injury unexplained recurrent loss consciousness ≥15 minute Epilepsy Major depressive disorder , schizophrenia , psychotic disorder , bipolar disorder , substance ( include alcohol ) relate disorder Metal implant head ( except dental ) , pacemaker , cochlear implant , nonremovable item contraindication MRI Resides hospital moderate high dependency continuous care facility History swallow difficulty Pregnant breastfeed Glucose6phosphate dehydrogenase deficiency History significant hematological abnormality current acute chronic clinically significant abnormality Abnormal serum chemistry laboratory value Screening deem clinically relevant investigator Clinically significant cardiovascular disease abnormal assessment Preexisting current sign symptom respiratory failure Concurrent acute chronic clinically significant immunologic , hepatic , endocrine disease ( adequately treat ) and/or unstable major disease Alzheimer 's disease Diagnosis cancer within past 2 year prior Baseline ( basal cell squamous cell skin cancer Stage 1 prostate cancer ) unless treatment result complete freedom disease least 2 year Prior intolerance hypersensitivity methylthioniniumcontaining drug , similar organic dye , excipients Treatment currently within 3 month Baseline follow medication : Tacrine Clozapine , olanzapine ( intent initiate therapy course study ) Carbamazepine , primidone Drugs warn precaution label methemoglobinemia approve dos Current prior participation clinical trial follow : Clinical trial product cognition within 3 month Screening ( unless confirm randomized placebo ) A clinical trial drug , biologic , therapeutic device , medical food last dose/administration receive within 28 day prior Baseline</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Alzheimer Disease</keyword>
	<keyword>TRx0237</keyword>
	<keyword>AD</keyword>
	<keyword>Neurodegenerative Diseases</keyword>
	<keyword>Dementia</keyword>
	<keyword>Brain Diseases</keyword>
</DOC>